The three-year deal with Insilico will aim to transform data generated every day into measurable improvements to production processes
Teva Pharmaceutical Industries has signed an agreement to use Insilico’s ‘Digital Twins’ technology to improve biopharmaceutical therapeutics production processes.
The ever-increasing demand for high-quality biopharmaceutical therapies such as monoclonal antibodies requires highly efficient and robust production technologies.
Digital transformation of the biopharmaceutical sector generates large amounts of data from bioprocessing. The use of Insilico Digital Twins is able to transform this wealth of process data, generated every day, into measurable improvements in the production process.
US-based Insilico’s Digital Twins of biopharmaceutical production processes employ metabolic models of producer organisms, in combination with flexible process models and artificial intelligence to create optimised production processes by computational simulations. The company said its Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness.
Jason Bock, VP of Biologics CMC at Teva, said: “By complementing our process development capabilities with Insilico’s unique technology for digital bioprocess development we can accomplish robust and efficient production of our biologics pipeline faster. Saving experimental efforts and time perfectly fits the accelerated timelines in clinical development that we are seeing now and even more in the future.”
The collaboration will run for three years and will be based at Insilico's sites in Stuttgart, Germany and at Isreal-based Teva’s West Chester, US, location.